Skip to main content
SpringerLink
Log in

Drug-Induced Nephrotoxicity

  • Chapter
  • First Online:
Renal Medicine and Clinical Pharmacy

Abstract

Drug-induced nephrotoxicity (DIN) is a relatively common adverse drug event that contributes to morbidity and increased healthcare utilisation. The phenotypes of DIN comprise acute kidney injury, tubular disorders, glomerular injury, and nephrolithiasis. The common risk factors of DIN include age, causal drug use, single and/or cumulative dosage, an underlying chronic kidney disease, comorbid diseases, and concurrent nephrotoxin exposures. Therefore, minimising the exposure to these risk factors may mitigate the development of DIN as it is an important and potentially modifiable renal adverse drug event. Identifying the medications that induce nephrotoxicity is essential in clinical practice. The clinical pharmacist, therefore, should understand and identify patients who are at the highest risk of developing DIN, implement the judicious use of nephrotoxic medications, and conduct frequent monitoring of such patients. The latter role of the pharmacist is especially important when a combination of nephrotoxic drugs is being used by a patient. For patients with confirmed DIN, the use of nephrotoxic drugs should be greatly avoided, to aid renal recovery and prevent recurrent DIN.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Awdishu L. Drug-induced kidney disease in the ICU: mechanisms, susceptibility, diagnosis and management strategies. Curr Opin Crit Care. 2017;23(6):484–90.

    PubMed  Google Scholar 

  • Awdishu L, Mehta RL. The 6R’s of drug induced nephrotoxicity. BMC Nephrol. 2017;18(1):124.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Barreto EF, Rule AD, Voils SA, Kane-Gill SL. Innovative use of novel biomarkers to improve the safety of Renally eliminated and nephrotoxic medications. Pharmacotherapy. 2018;38(8):794–803.

    CAS  PubMed  Google Scholar 

  • Bartoli E. Adverse effects of drugs on the kidney. Eur J Intern Med. 2016;28:1–8.

    PubMed  Google Scholar 

  • Bentley ML, Corwin HL, Dasta J. Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies. Crit Care Med. 2010;38(6 Suppl):S169–74.

    CAS  PubMed  Google Scholar 

  • Blatt A, Liebman SE. Drug-induced acute kidney injury. Hosp Med Clin. 2013;2(4):e525–41.

    Google Scholar 

  • Burgess LD, Drew RH. Comparison of the incidence of vancomycin-induced nephrotoxicity in hospitalized patients with and without concomitant piperacillin-tazobactam. Pharmacotherapy. 2014;34(7):670–6.

    CAS  PubMed  Google Scholar 

  • Cabanillas F, Burgos RC, Rodríguez C, Baldizón C. Nephrotoxicity of combined cephalothin-gentamicin regimen. Arch Intern Med. 1975;135(6):850–2.

    CAS  PubMed  Google Scholar 

  • Cartin-Ceba R, Kashiouris M, Plataki M, Kor DJ, Gajic O, Casey ET. Risk factors for development of acute kidney injury in critically ill patients: a systematic review and meta-analysis of observational studies. Crit Care Res Pract. 2012;2012:691013. https://doi.org/10.1155/2012/691013.

    Article  PubMed  PubMed Central  Google Scholar 

  • Chawla LS, Bellomo R, Bihorac A, Goldstein SL, Siew ED, Bagshaw SM, Bittleman D, Cruz D, Endre Z, Fitzgerald RL, Forni L, Kane-Gill SL, Hoste E, Koyner J, Liu KD, Macedo E, Mehta R, Murray P, Nadim M, Ostermann M, Palevsky PM, Pannu N, Rosner M, Wald R, Zarbock A, Ronco C, Kellum JA. Acute disease quality initiative workgroup 16. Acute kidney disease and renal recovery: consensus report of the Acute disease quality initiative (ADQI) 16 workgroup. Nat Rev Nephrol. 2017;13(4):241–57.

    PubMed  Google Scholar 

  • Christensen ML, Stewart CF, Crom WR. Evaluation of aminoglycoside disposition in patients previously treated with cisplatin. Ther Drug Monit. 1989;11(6):631–6.

    CAS  PubMed  Google Scholar 

  • Coulter CV. The role of the suspicious renal pharmacist in identifying unusual adverse drug reactions-why this is not a small problem. Int J Clin Pharm. 2018;40(4):775–7.

    PubMed  Google Scholar 

  • Daudon M, Frochot V, Bazin D, Jungers P. Drug-induced kidney stones and crystalline nephropathy: pathophysiology, prevention and treatment. Drugs. 2018;78(2):163–201.

    CAS  PubMed  Google Scholar 

  • Delanaye P, Guerber F, Scheen A, Ellam T, Bouquegneau A, Guergour D, Mariat C, Pottel H. Discrepancies between the Cockcroft-gault and chronic kidney disease epidemiology (CKD-EPI) equations: implications for refining drug dosage adjustment strategies. Clin Pharmacokinet. 2017;56(2):193–205.

    PubMed  Google Scholar 

  • Dickenmann M, Oettl T, Mihatsch MJ. Osmotic nephrosis: acute kidney injury with accumulation of proximal tubular lysosomes due to administration of exogenous solutes. Am J Kidney Dis. 2008;51(3):491–503.

    PubMed  Google Scholar 

  • Elston RA, Taylor J. Possible interaction of ciprofloxacin with cyclosporin. J Antimicrob Chemother. 1988;21(5):679–80.

    CAS  PubMed  Google Scholar 

  • Eppenga WL, Kramers C, Derijks HJ, Wensing M, Wetzels JF, De Smet PA. Drug therapy management in patients with renal impairment: how to use creatinine-based formulas in clinical practice. Eur J Clin Pharmacol. 2016;72(12):1433–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Fanos V, Cataldi L. Renal transport of antibiotics and nephrotoxicity: a review. J Chemother. 2001;13(5):461–72.

    CAS  PubMed  Google Scholar 

  • Faught LN, Greff MJ, Rieder MJ, Koren G. Drug-induced acute kidney injury in children. Br J Clin Pharmacol. 2015;80(4):901–9.

    PubMed  PubMed Central  Google Scholar 

  • Fillastre JP, Laumonier R, Humbert G, Dubois D, Metayer J, Delpech A, Leroy J, Robert M. Acute renal failure associated with combined gentamicin and cephalothin therapy. Br Med J. 1973;2(5863):396–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Gandhi S, Fleet JL, Bailey DG, McArthur E, Wald R, Rehman F, Garg AX. Calcium-channel blocker-clarithromycin drug interactions and acute kidney injury. JAMA. 2013;310(23):2544–53.

    CAS  PubMed  Google Scholar 

  • Girardi A, Raschi E, Galletti S, Poluzzi E, Faldella G, Allegaert K, De Ponti F. Drug-induced renal damage in preterm neonates: state of the art and methods for early detection. Drug Saf. 2015;38(6):535–51.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Girardi A, Raschi E, Galletti S, Allegaert K, Poluzzi E, De Ponti F. Drug-induced renal injury in neonates: challenges in clinical practice and perspectives in drug development. Expert Opin Drug Metab Toxicol. 2017;13(5):555–65.

    CAS  PubMed  Google Scholar 

  • Glanzmann C, Frey B, Vonbach P, Meier CR. Drugs as risk factors of acute kidney injury in critically ill children. Pediatr Nephrol. 2016;31(1):145–51.

    PubMed  Google Scholar 

  • Guo X, Nzerue C. How to prevent, recognize, and treat drug-induced nephrotoxicity. Cleve Clin J Med. 2002;69(4):289–90, 293-4, 296-7 passim

    PubMed  Google Scholar 

  • Hall AM, Bass P, Unwin RJ. Drug-induced renal Fanconi syndrome. QJM. 2014;107(4):261–9.

    CAS  PubMed  Google Scholar 

  • Hamill RJ. Amphotericin B formulations: a comparative review of efficacy and toxicity. Drugs. 2013;73(9):919–3.

    CAS  PubMed  Google Scholar 

  • Haque SK, Ariceta G, Batlle D. Proximal renal tubular acidosis: a not so rare disorder of multiple etiologies. Nephrol Dial Transplant. 2012;27(12):4273–87.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Honore PM, Spapen HD. What a clinician should know about a renal replacement membrane? J Transl Int Med. 2018;6(2):62–5.

    Google Scholar 

  • Hosohata K, Inada A, Oyama S, Furushima D, Yamada H, Iwanaga K. Surveillance of drugs that most frequently induce acute kidney injury: a pharmacovigilance approach. J Clin Pharm Ther. 2019;44(1):49–53.

    Google Scholar 

  • Hoste EA, Bagshaw SM, Bellomo R, Cely CM, Colman R, Cruz DN, Edipidis K, Forni LG, Gomersall CD, Govil D, Honoré PM, Joannes-Boyau O, Joannidis M, Korhonen AM, Lavrentieva A, Mehta RL, Palevsky P, Roessler E, Ronco C, Uchino S, Vazquez JA, Vidal Andrade E, Webb S, Kellum JA. Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study. Intensive Care Med. 2015;41(8):1411–23.

    PubMed  Google Scholar 

  • Hsu CN, Lee CT, Su CH, Wang YC, Chen HL, Chuang JH, Tain YL. Incidence, outcomes, and risk factors of community-acquired and hospital-acquired acute kidney injury: a retrospective cohort study. Medicine (Baltimore). 2016;95(19):e3674.

    Google Scholar 

  • Hudson JQ, Nolin TD. Pragmatic use of kidney function estimates for drug dosing: the tide is turning. Adv Chronic Kidney Dis. 2018;25(1):14–20.

    PubMed  Google Scholar 

  • Izzedine H, Perazella MA. Anticancer drug-induced acute kidney injury. Kidney Int Rep. 2017a;2(4):504–14.

    PubMed  PubMed Central  Google Scholar 

  • Izzedine H, Perazella MA. Adverse kidney effects of epidermal growth factor receptor inhibitors. Nephrol Dial Transplant. 2017b;32(7):1089–97.

    CAS  PubMed  Google Scholar 

  • Izzedine H, Hulot JS, Villard E, Goyenvalle C, Dominguez S, Ghosn J, Valantin MA, Lechat P, Deray AG. Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy. J Infect Dis. 2006;194(11):1481–91.

    CAS  PubMed  Google Scholar 

  • Jerkić M, Vojvodić S, López-Novoa JM. The mechanism of increased renal susceptibility to toxic substances in the elderly. Part I. the role of increased vasoconstriction. Int Urol Nephrol. 2001;32(4):539–47.

    PubMed  Google Scholar 

  • Joyce EL, Kane-Gill SL, Fuhrman DY, Kellum JA. Drug-associated acute kidney injury: who’s at risk? Pediatr Nephrol. 2017;32(1):59–69.

    PubMed  Google Scholar 

  • Kane-Gill SL, Bauer SR. AKD-the time between AKI and CKD: what is the role of the pharmacist? Hosp Pharm. 2017;52(10):663–5.

    PubMed  PubMed Central  Google Scholar 

  • Kane-Gill SL, Goldstein SL. Drug-induced acute kidney injury: a focus on risk assessment for prevention. Crit Care Clin. 2015;31(4):675–84.

    PubMed  Google Scholar 

  • Khan S, Loi V, Rosner MH. Drug-induced kidney injury in the elderly. Drugs Aging. 2017;34(10):729–41.

    CAS  PubMed  Google Scholar 

  • Kidney Disease. Improving global outcomes (KDIGO) Acute kidney injury work group. KDIGO clinical practice guideline for Acute kidney injury. Kidney Int. 2012;2:1–138.

    Google Scholar 

  • Koyner JL, Garg AX, Thiessen-Philbrook H, Coca SG, Cantley LG, Peixoto A, Passik CS, Hong K, Parikh CR1; TRIBE-AKI consortium. Adjudication of etiology of acute kidney injury: experience from the TRIBE-AKI multi-center study.BMC Nephrol. 2014;15:105. doi: https://doi.org/10.1186/1471-2369-15-105.

  • Kusus M, Stapleton DD, Lertora JJ, Simon EE, Dreisbach AW. Rhabdomyolysis and acute renal failure in a cardiac transplant recipient due to multiple drug interactions. Am J Med Sci. 2000;320(6):394–7.

    CAS  PubMed  Google Scholar 

  • Lapi F, Azoulay L, Yin H, Nessim SJ, Suissa S. Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: nested case-control study. BMJ. 2013;346:e8525.

    PubMed  PubMed Central  Google Scholar 

  • Lee HC, Pettinger WA. Diuretics potentiate the angiotensin converting-enzyme inhibitor-associated acute renal dysfunction. Clin Nephrol. 1992;38(4):236–7.

    CAS  PubMed  Google Scholar 

  • Luther MK, Timbrook TT, Caffrey AR, Dosa D, Lodise TP, LaPlante KL. Vancomycin plus Piperacillin-Tazobactam and Acute kidney injury in adults: a systematic review and meta-analysis. Crit Care Med. 2018;46(1):12–20.

    CAS  PubMed  Google Scholar 

  • Maiche AG. Acute renal failure due to concomitant action of methotrexate and indomethacin. Lancet. 1986;1(8494):1390.

    CAS  PubMed  Google Scholar 

  • Markowitz GS, Bomback AS, Perazella MA. Drug-induced glomerular disease: direct cellular injury. Clin J Am Soc Nephrol. 2015;10(7):1291–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Matzke GR, Aronoff GR, Atkinson AJ Jr, Bennett WM, Decker BS, Eckardt KU, Golper T, Grabe DW, Kasiske B, Keller F, Kielstein JT, Mehta R, Mueller BA, Pasko DA, Schaefer F, Sica DA, Inker LA, Umans JG, Murray P. Drug dosing consideration in patients with acute and chronic kidney disease-a clinical update from kidney disease: improving global outcomes (KDIGO). Kidney Int. 2011;80(11):1122–37. https://doi.org/10.1038/ki.2011.322.

    Article  CAS  PubMed  Google Scholar 

  • McWilliam SJ, Antoine DJ, Smyth RL, Pirmohamed M. Aminoglycoside-induced nephrotoxicity in children. Pediatr Nephrol. 2017;32(11):2015–25.

    PubMed  Google Scholar 

  • Mehta RL, Awdishu L, Davenport A, Murray PT, Macedo E, Cerda J, Chakaravarthi R, Holden AL, Goldstein SL. Phenotype standardization for drug-induced kidney disease. Kidney Int. 2015;88(2):226–34.

    PubMed  PubMed Central  Google Scholar 

  • Nagai J, Takano M. Molecular aspects of renal handling of aminoglycosides and strategies for preventing the nephrotoxicity. Drug Metab Pharmacokinet. 2004;19(3):159–70.

    CAS  PubMed  Google Scholar 

  • Nasir M, Rotellar C, Hand M, Kulczycki L, Alijani MR, Winchester JF. Interaction between ciclosporin and ciprofloxacin. Nephron. 1991;57(2):245–6.

    CAS  PubMed  Google Scholar 

  • Orbach H, Tishler M, Shoenfeld Y. Intravenous immunoglobulin and the kidney--a two-edged sword. Semin Arthritis Rheum. 2004;34(3):593–601.

    CAS  PubMed  Google Scholar 

  • Ostermann M, Chawla LS, Forni LG, Kane-Gill SL, Kellum JA, Koyner J, Murray PT, Ronco C, Goldstein SL. ADQI 16 workgroup. Drug management in acute kidney disease – report of the Acute disease quality initiative XVI meeting. Br J Clin Pharmacol. 2018;84(2):396–403.

    PubMed  Google Scholar 

  • Oyama S, Hosohata K, Inada A, Niinomi I, Mori Y, Yamaguchi Y, Uchida M, Iwanaga K. Drug-induced tubulointerstitial nephritis in a retrospective study using spontaneous reporting system database. Ther Clin Risk Manag. 2018;14:1599–604.

    PubMed  PubMed Central  Google Scholar 

  • Patel AM, Shariff S, Bailey DG, Juurlink DN, Gandhi S, Mamdani M, Gomes T, Fleet J, Hwang YJ, Garg AX. Statin toxicity from macrolide antibiotic coprescription: a population-based cohort study. Ann Intern Med. 2013;158(12):869–76.

    PubMed  Google Scholar 

  • Paueksakon P, Fogo AB. Drug-induced nephropathies. Histopathology. 2017;70(1):94–108.

    PubMed  Google Scholar 

  • Perazella MA. Pharmacology behind common drug Nephrotoxicities. Clin J Am Soc Nephrol. 2018;13(12):1897–1908.

    Google Scholar 

  • Perazella MA, Rosner MH. Acute kidney injury in patients with Cancer. Oncology (Williston Park). 2018;32(7):351–9.

    Google Scholar 

  • Perazella MA, Shirali AC. Nephrotoxicity of Cancer immunotherapies: past, present and future. J Am Soc Nephrol. 2018;29(8):2039–52.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Redahan L, Murray PT. Novel biomarkers of drug-induced kidney injury. Clin Pharmacol Ther. 2018;103(3):396–8.

    PubMed  Google Scholar 

  • Rivosecchi RM, Kellum JA, Dasta JF, Armahizer MJ, Bolesta S, Buckley MS, Dzierba AL, Frazee EN, Johnson HJ, Kim C, Murugan R, Smithburger PL, Wong A, Kane Gill SL. Drug class combination-associated Acute kidney injury. Ann Pharmacother. 2016;50(11):953–72.

    CAS  PubMed  Google Scholar 

  • Rosner MH, Perazella MA. Acute kidney injury in patients with Cancer. N Engl J Med. 2017;376(18):1770–81.

    CAS  PubMed  Google Scholar 

  • Rossignol P, Cleland JG, Bhandari S, Tala S, Gustafsson F, Fay R, Lamiral Z, Dobre D, Pitt B, Zannad F. Determinants and consequences of renal function variations with aldosterone blocker therapy in heart failure patients after myocardial infarction: insights from the Eplerenone post-Acute myocardial infarction heart Failure efficacy and survival study. Circulation. 2012;125(2):271–9.

    CAS  PubMed  Google Scholar 

  • Rougier F, Ducher M, Maurin M, Corvaisier S, Claude D, Jelliffe R, Maire P. Aminoglycoside dosages and nephrotoxicity: quantitative relationships. Clin Pharmacokinet. 2003;42(5):493–500.

    CAS  PubMed  Google Scholar 

  • Scarfia RV, Clementi A, Granata A. Rhabdomyolysis and acute kidney injury secondary to interaction between simvastatin and cyclosporine. Ren Fail. 2013;35(7):1056–7.

    CAS  PubMed  Google Scholar 

  • Schissler MM, Zaidi S, Kumar H, Deo D, Brier ME, McLeish KR. Characteristics and outcomes in community-acquired versus hospital-acquired acute kidney injury. Nephrology. 2013;18(3):183–7.

    PubMed  Google Scholar 

  • Schneider M, Valentine S, Clarke GM, Newman MA, Peacock J. Acute renal failure in cardiac surgical patients, potentiated by gentamicin and calcium. Anaesth Intensive Care. 1996;24(6):647–50.

    CAS  PubMed  Google Scholar 

  • Shepshelovich D, Schechter A, Calvarysky B, Diker-Cohen T, Rozen-Zvi B, Gafter-Gvili A. Medication-induced SIADH: distribution and characterization according to medication class. Br J Clin Pharmacol. 2017;83(8):1801–180.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Siew ED, Davenport A. The growth of acute kidney injury: a rising tide or just closer attention to detail? Kidney Int. 2015;87(1):46–61.

    PubMed  Google Scholar 

  • Singh RR, Malaviya AN, Pandey JN, Guleria JS. Fatal interaction between methotrexate and naproxen. Lancet. 1986;1(8494):1390.

    CAS  PubMed  Google Scholar 

  • Steinhäuslin F, Munafo A, Buclin T, Macciocchi A, Biollaz J. Renal effects of nimesulide in furosemide-treated subjects. Drugs. 1993;46(Suppl 1):257–62.

    PubMed  Google Scholar 

  • Suk R, Gurubhagavatula S, Park S, Zhou W, Su L, Lynch TJ, Wain JC, Neuberg D, Liu G, Christiani DC. Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patients. Clin Cancer Res. 2005;11(4):1534–8.

    CAS  PubMed  Google Scholar 

  • Susla GM. The impact of continuous renal replacement therapy on drug therapy. Clin Pharmacol Ther. 2009;86(5):562–5. https://doi.org/10.1038/clpt.2009.152.

    Article  CAS  PubMed  Google Scholar 

  • Teutonico A, Libutti P, Lomonte C, Basile C. Simvastatin-induced myoglobinuric acute kidney injury following ciclosporin treatment for alopecia universalis. NDT Plus. 2010;3(3):273–5.

    PubMed  PubMed Central  Google Scholar 

  • Uchino S, Kellum JA, Bellomo R, Doig GS, Morimatsu H, Morgera S, Schetz M, Tan I, Bouman C, Macedo E, Gibney N, Tolwani A, Ronco C. Beginning and ending supportive therapy for the kidney (BEST kidney) investigators. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA. 2005;294(7):813–8.

    CAS  PubMed  Google Scholar 

  • VA/NIH Acute Renal Failure Trial Network, Palevsky PM, Zhang JH, O’Connor TZ, Chertow GM, Crowley ST, Choudhury D, Finkel K, Kellum JA, Paganini E, Schein RM, Smith MW, Swanson KM, Thompson BT, Vijayan A, Watnick S, Star RA, Peduzzi P. Intensity of renal support in critically ill patients with acute kidney injury. N Engl J Med. 2008;359(1):7–20.

    Google Scholar 

  • Wang YC, Hsieh TC, Chou CL, Wu JL, Fang TC. Risks of adverse events following Coprescription of statins and Calcium Channel blockers: a Nationwide population-based study. Medicine (Baltimore). 2016;95(2):e2487.

    CAS  Google Scholar 

  • Welch HK, Kellum JA, Kane-Gill SL. Drug-associated Acute kidney injury identified in the United States Food and Drug Administration adverse event reporting system database. Pharmacotherapy. 2018 Aug;38(8):785–93.

    CAS  PubMed  Google Scholar 

  • Wrenger E, Müller R, Moesenthin M, Welte T, Frölich JC, Neumann KH. Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: analysis of 44 cases. BMJ. 2003;327(7407):147–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Zavascki AP, Nation RL. Nephrotoxicity of Polymyxins: is there any difference between Colistimethate and Polymyxin B? Antimicrob Agents Chemother. 2017;61(3)

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmaceutical Products, Faculty of Pharmacy, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil

    Adriano Max Moreira Reis

Authors
  1. Adriano Max Moreira Reis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Adriano Max Moreira Reis .

Editor information

Editors and Affiliations

  1. University of Otago, Dunedin, New Zealand

    Rhiannon Braund

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Reis, A.M.M. (2020). Drug-Induced Nephrotoxicity. In: Braund, R. (eds) Renal Medicine and Clinical Pharmacy. Advanced Clinical Pharmacy - Research, Development and Practical Applications, vol 1. Springer, Cham. https://doi.org/10.1007/978-3-030-37655-0_6

Download citation

Publish with us

Policies and ethics

Search

Navigation